Warning! GuruFocus detected
1 Severe warning sign
with 3DMA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Kintara Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US49720K2006
Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.61 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 80.2 | |||||
| 3-Year EPS without NRI Growth Rate | 81.2 | |||||
| 3-Year FCF Growth Rate | 80.3 | |||||
| 3-Year Book Growth Rate | 74 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 64.43 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.32 | |||||
| 9-Day RSI | 64.12 | |||||
| 14-Day RSI | 59.74 | |||||
| 3-1 Month Momentum % | -41.27 | |||||
| 6-1 Month Momentum % | 53.09 | |||||
| 12-1 Month Momentum % | -95.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.45 | |||||
| Quick Ratio | 2.45 | |||||
| Cash Ratio | 2.17 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -338.7 | |||||
| Shareholder Yield % | -88.21 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -506.08 | |||||
| ROA % | -198.2 | |||||
| ROIC % | -1218.78 | |||||
| 3-Year ROIIC % | -1219.42 | |||||
| ROC (Joel Greenblatt) % | -1218.78 | |||||
| ROCE % | -464.29 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -2.05 | |||||
| EV-to-EBITDA | -2.06 | |||||
| EV-to-Forward-Revenue | 0.85 | |||||
| EV-to-FCF | -2.42 | |||||
| Price-to-Net-Cash | 173.77 | |||||
| Earnings Yield (Greenblatt) % | -48.78 | |||||
| FCF Yield % | -59.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kintara Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.02 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -0.72 | ||
| 3-Year Sortino Ratio | -0.93 | ||
| Volatility % | 155.91 | ||
| 14-Day RSI | 59.74 | ||
| 14-Day ATR (€) | 0.528628 | ||
| 20-Day SMA (€) | 5.773949 | ||
| 12-1 Month Momentum % | -95.99 | ||
| 52-Week Range (€) | 2.449999 - 140.699999 | ||
| Shares Outstanding (Mil) | 55.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kintara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kintara Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kintara Therapeutics Inc Frequently Asked Questions
What is Kintara Therapeutics Inc(FRA:3DMA)'s stock price today?
The current price of FRA:3DMA is €6.95. The 52 week high of FRA:3DMA is €140.70 and 52 week low is €2.45.
When is next earnings date of Kintara Therapeutics Inc(FRA:3DMA)?
The next earnings date of Kintara Therapeutics Inc(FRA:3DMA) is 2025-05-14 Est..
Does Kintara Therapeutics Inc(FRA:3DMA) pay dividends? If so, how much?
Kintara Therapeutics Inc(FRA:3DMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers